Amanote Research
Register
Sign In
P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.10.044
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
December 1, 2018
Authors
H. Yang
C. Zhou
Y. Su
Z. Zhou
P. Chen
M. Yang
C. Li
W. Guo
W. Zhao
K. Lu
J. Yin
J. Chen
Z. Li
X. Yu
X. Xu
J. Xiang
T. Zhang
B. Li
L. Zhang
H. Liu
N. Yang
Publisher
Elsevier BV
Related search
Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA07 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-61 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary